Damora Therapeutics (DMRA) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Damora Therapeutics (DMRA) over the past year, gaining 17.4% versus a gain of 12.9%. Over five years, NBTX leads with a +92.0% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.17 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | NBTX |
|---|---|---|
| Share price | $20.56 | $22.90 |
| Market cap | $1.27B | $1.17B |
| 1-day change | +1.58% | -6.99% |
| YTD return | -12.04% | +6.49% |
| 1-year return | +12.95% | +17.41% |
| 5-year return | -76.33% | +92.04% |
| EPS (TTM) | $-0.25 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $57.14 |
| 52-week low | $4.95 | $14.78 |
| Distance from 52-week high | -46.35% | -59.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.06% | +135.28% |
| Average volume | 539.81K | 148.97K |
| Shares outstanding | 61.74M | 50.92M |
| Employees | 7 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
DMRA vs NBTX FAQ
Which is bigger, Damora Therapeutics or Nanobiotix S.A.?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.17B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, DMRA or NBTX?
NBTX returned +17.41% over the past 12 months, compared with +12.95% for DMRA (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.